ClinicalTrials.gg
CompletedNCT03562117Updated Apr 12, 2021Results posted

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

A Phase 1 interventional study of Gepotidacin in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-12.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.

Enrollment
8th of 11
25 · median 34
Started
2018
with 1 other
Phase 1
9 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
10 of 11
GlaxoSmithKline

Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 1, and was the 6th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About gepotidacin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing gepotidacin in Bacterial Infections, or all of them as a file.
02

Study summary

This is a two-part study which will evaluate the PK, safety, and tolerability of a single 1500 milligram (mg) oral dose of gepotidacin in subjects with normal hepatic function and in subjects with mild, moderate, and severe hepatic impairment. In Part 1, subjects with moderate hepatic impairment and subjects with normal hepatic function will be enrolled. Matching subjects with normal hepatic function in Part 1 (Group D), will be enrolled following the completion of all Day 3 assessments of the respective matched, hepatically impaired subject. In Part 2, subjects with mild (optional) and severe hepatic impairment and subjects with normal hepatic function will be enrolled concurrently based on the PK, safety, and tolerability data of Part 1. Subjects with mild hepatic impairment, may be studied if there is a significant difference in PK between subjects with moderate hepatic impairment and subjects with normal hepatic function. Subjects with severe hepatic impairment, will be studied in Part 2, provided that, the PK objectives are achieved in Part 1. A totals of 48 subjects, are planned to be enrolled in the study. The study duration is approximately of 44 days from Screening to Follow-up visit. The results from this study will enable the development of appropriate dosing recommendations in subjects with impaired hepatic function.

03

Conditions studied

  • Infections, Bacterial

Browse trials for

Keywords

  • Child-Pugh classification
  • Open label
  • Hepatic Impairment
  • Gepotidacin
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be 18 to 80 years of age inclusive, at the time of signing the .
  • Healthy subjects must be in clinically stable health as determined by the investigator based on medical history, clinical laboratory results (serum chemistry, hematology, urinalysis, and serology), vital sign measurements, 12-lead results, and physical examination findings.
  • Hepatically impaired subjects must have chronic (>6 months), stable (no acute episodes of illness within the previous 1 month prior to screening due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology. Subjects must also remain stable throughout the Screening period.
  • Hepatically impaired subjects, will be classified, using the classification system. Subjects must have, a Child-Pugh score, of 5 to 6 (mild hepatic impairment), 7 to 9 (moderate hepatic impairment), or 10 to 15 (severe hepatic impairment), with known medical history of liver disease (with or without a known history of alcohol abuse), and previous confirmation of liver cirrhosis by liver or other medical imaging technique (including laparoscopy, computed tomography scan, magnetic resonance imaging, or ultrasonography) associated with unambiguous medical history. If imaging study, or biopsy is not available, then the subject should have one of the following: Physical findings such as hepatomegaly, ascites, palmar erythema, spider angiomata, abdominal venous collaterals, gynecomastia, or other physical manifestations of hepatic disease Or Laboratory findings: or AST elevation (> [ULN]), alkaline phosphatase, or total , or (INR) elevation (>ULN) or an albumin value that is below the lower limit of normal laboratory reference range.
  • Subjects with hepatic impairment may be taking medications, which in the opinion of the investigator, are believed to be therapeutic, and these medications should not interfere with the conduct of the study. Subjects with hepatic impairment should be on stable regimen of chronic medications for at least 7 days prior to dosing until completion of the Follow-Up Visit.
  • Subjects with hepatic impairment must have counts of 30,000 × 109/Liter of blood and have not had any major bleeding episodes within the past 6 months.
  • Body weight >=45 kilogram (kg) and (BMI) within the range 18.5 to 40 kg/meter\^2 (inclusive).
  • Male subjects must agree to use , as protocol from Day -1 until completion of the Follow-up Visit or, female subject will be eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applied Not a woman of (WOCBP) or A WOCBP who agrees to follow the contraceptive guidance from 30 days prior to study drug administration and until completion of the Follow-up Visit.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Subject has a abnormality in past medical history or at the Screening physical examination (excluding hepatic insufficiency and other related medical conditions within the hepatically impaired populations, which should be stable for at least 1 month before study drug administration), that in the investigator's opinion, may place the subject at risk or interfere with outcome variables of the study. This includes, but is not limited to, history or current significant cardiac, renal, neurologic, gastrointestinal, respiratory, hematologic, or immunologic disease.
  • Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk, in the opinion of the investigator.
  • Female subject, has a positive pregnancy test result or is lactating at Screening or upon admission to the clinic.
  • Subject has used a systemic antibiotic within 7 days of Screening.
  • Subject has a confirmed history of Clostridium (C) difficile infection or a positive C. difficile toxin test, within 2 months before Screening.
  • Subject has a history of drug and/or alcohol abuse within 6 months before Screening, as determined by the investigator, or subject has a positive drug screen at Screening or upon admission to the clinic. For subjects with hepatic impairment, and a positive drug screen result related to the use of prescription medications, is allowed per investigator review and approval, and tetrahydrocannabinol use is allowed per investigator review and approval.
  • History of sensitivity to any of the study drugs, components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinic uses heparin to maintain intravenous cannula patency).
  • Subject has used medications known to affect the elimination of serum creatinine (example (e.g); trimethoprim or cimetidine) or competitors of renal tubular secretion (e.g., probenecid) within 30 days before dosing.
  • Subject must abstain from taking prescription or nonprescription drugs (including vitamins and dietary or herbal supplements), unless specified, within 7 days (or 14 days if the drug is a potential strong enzyme inducer) or 5 half-lives (whichever is longer) prior to study drug administration until completion of the Follow-Up Visit, unless, in the opinion of the investigator and Sponsor, the medication will not interfere with the study. Any exceptions (including subjects with hepatic impairment that will be on medications during the study), will be discussed with the sponsor or medical monitor on a case-by-case basis and the reasons will be documented.
  • Previous exposure to gepotidacin, within 12 months prior to study drug administration.
  • Subject has participated in a clinical trial and has received an product within the following time period prior to study drug administration in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Subject with normal hepatic function has presence of surface antigen or positive antibody test result at Screening or within 3 months prior to study drug administration. Subject with hepatic impairment has evidence of recent, acute infection with hepatitis B and/or hepatitis C within preceding 6 months. Hepatically impaired subjects with chronic hepatitis B or C (duration >6 months) will be eligible for enrolment.
  • A positive test for antibody.
  • Subject must be able to abstain from alcohol and limit use of nicotine and/or nicotine-containing products (up to 5 cigarettes/day is acceptable for subjects with hepatic impairment) for 24 hours before the start of dosing until after collection of the final PK sample. A positive alcohol or cotinine test is not exclusionary for subjects with hepatic impairment.
  • Subject has clinically significant abnormal findings in serum chemistry, hematology, or urinalysis results obtained at Screening or Day -1, other than those associated with underlying hepatic conditions or other stable medical conditions consistent with the disease process in subjects with hepatic impairment.
  • Subject with normal hepatic function has a baseline interval using the Fridericia formula (QTcF) of >450 milliseconds (msec) and subject with hepatic impairment has a baseline QTcF of >480 msec.
  • Donation of blood in excess of 500 milliliter (mL) within 12 weeks prior to dosing or participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56-day period.
  • Subject is unable to comply with all study procedures, in the opinion of the investigator.
  • Subject should not participate in the study, in the opinion of the investigator or Sponsor.
  • Subjects with a pre-existing condition (except hepatic impairment) interfering with normal gastrointestinal (GI) anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of inflammatory bowel disease should be excluded. Subjects with a history of pepticulceration or pancreatitis within the preceding 6 months of screening, should be excluded.
  • Subject with any previous GI surgery (except appendectomy or gall bladder removal >3 months prior to Screening) may be enrolled in this study only if, in the opinion of the investigator and the medical monitor, it is not expected to interfere with the study procedures or to pose an additional safety risk to the subject.
  • Subject receiving lactulose who are medically unable to halt lactulose administration from 8 hours before dosing with study drug to 4 hours after dosing with study drug.
  • Subjects with clinically active severe encephalopathy (grade 3 or 4) as judged by the investigator or significant central nervous system disease (e.g., dementia or seizures) which the investigator considers will interfere with the , conduct, completion, or results of this trial or constitutes an unacceptable risk to the subject. Subjects with a prior history of severe encephalopathy, who are currently treated for this condition will receive the appropriate score for encephalopathy.
  • Subjects with estimated (Clcr) \<=50 mL/minute (calculated by the Cockcroft-Gault Formula). If the result calculated by Cockcroft-Gault is between 40 and 50 mL/minute, then the site may complete a 24-hour urine collection to more specifically calculate the Clcr. A Clcr value \<=50 mL/minute via 24-hour urine collection is also exclusionary.
  • History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures.
  • Subjects with electrolyte imbalance whose serum sodium levels are \<=125 millimole per Liter (mmol/L); potassium levels are \<=2.5 mmol/L; or calcium levels are \<=6.1 mmol/L.
  • Presence of hepatopulmonary or hepatorenal syndrome.
  • Primary cholestatic liver diseases.
  • History of liver transplantation or subjects in the severe hepatic impairment group that are expecting a liver transplant during the study participation period.
  • Subjects with signs of active bacterial infection (including active spontaneous bacterial peritonitis).
  • Subjects with transjugular intrahepatic portosystemic shunt placement within the past 3 months.
  • Subjects with unstable cardiac function or subjects with hypertension whose blood pressure, that is not well controlled (based on the investigator's discretion).
  • Diabetic subjects whose diabetes that is not controlled (based on the investigator's discretion).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Normal Hepatic function, Part 1 (Group D)

    The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.

    Drug: Gepotidacin

  • Experimental
    Moderate hepatic impairment, Part 1 (Group B)

    The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.

    Drug: Gepotidacin

  • Experimental
    Mild hepatic impairment, Part 2 (Group A)

    The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.

    Drug: Gepotidacin

  • Experimental
    Severe hepatic impairment, Part 2 (Group C)

    The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.

    Drug: Gepotidacin

  • Experimental
    Normal Hepatic function, Part 2 (Group E)

    The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.

    Drug: Gepotidacin

Interventions

  • It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate pharmacokinetic (PK) parameters. PK parameter population consist of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. This population was used in the assessment and characterization of PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  2. Maximum Observed Concentration (Cmax) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  2. Time to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  3. Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  4. Apparent Oral Clearance (CL/F) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  5. Apparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  6. Terminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  7. Terminal Phase Half Life (t1/2) for Plasma Gepotidacin

    Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  8. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Single 12-lead ECG was obtained in a semi-supine position after 5 minutes rest using an ECG machine. Safety Population consists of all participants who received at least 1 dose of study drug and had at least one postdose safety assessment. Number of participants with abnormal-clinically significant and abnormal-not clinically significant values has been presented. Absolute QTc Interval \>450 milliseconds (msec), absolute PR interval \<110 msec and absolute QRS interval \<75 msec was considered as clinically significant ECG findings.

    Time frame: 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  9. Change From Baseline Values in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs were measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  10. Change From Baseline Values in Heart Rate

    Vital signs was measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose

  11. Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment.

    Time frame: Up to Day 15

  12. Number of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters

    Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4, for urea, Creatine kinase (CK), creatinine, glucose, sodium, potassium, calcium, Aspartate Aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) levels, total and direct bilirubin, total protein, and albumin.

    Time frame: Up to Day 15

  13. Change From Baseline Values for Clinical Chemistry Parameters: ALT, ALP, AST and CK

    Blood samples were collected to analyze clinical chemistry parameters including: ALT, ALP, AST and CK. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Day 2

  14. Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected to analyze clinical chemistry parameters including albumin and protein. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Day 2

  15. Change From Baseline Values for Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected to analyze clinical chemistry parameters including bilirubin, direct bilirubin and creatinine. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Day 2

  16. Change From Baseline Values for Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Urea

    Blood samples were collected to analyze clinical chemistry parameters including calcium, glucose, potassium, sodium and urea. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Day 2

  17. Number of Participants With Toxicity Grading 3 or Higher for Hematology Parameters

    Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4 for blood neurtophils and blood platelets.

    Time frame: Up to 15 days

  18. Number of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters

    Urine samples were collected and specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones were analyzed by dipstick method.

    Time frame: Up to 15 days

  19. Number of Participants With Abnormal Findings During Physical Examinations

    A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

    Time frame: Pre-dose up to 31 days prior to dosing

  20. Total Unchanged Drug (Ae_total) and Amount of Drug Excreted in Urine in a Time Intervals (Ae (t1-t2) for Gepotidacin

    Urine samples were collected from participants at indicated time points. Ae_total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Ae (t1-t2) was the amount of drug excreted in urine in time intervals for predose, 0 to 6, 6 to 12, 12 to 24, 24 to 36, and 36 to 48 hours after dosing for participants with hepatic impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participants with normal hepatic function. It was calculated by multiplication of the urine concentration for a time interval and the length of this time interval.

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose

  21. Percentage of the Given Dose of Drug Excreted in Urine (Fe%)

    Urine samples were collected from participants at indicated time points. Percentage of the given dose of drug excreted in urine was calculated as: (Ae_total divided by Dose) and multiplied by 100.

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose

  22. Renal Clearance (CLr) of Gepotidacin

    Urine samples were collected from participants at indicated time points. Renal clearance for gepotidacin was calculated as Ae_total divided by AUC (0-t).

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose

  23. AUC(0-12) of Gepotidacin

    Urine samples were collected from participants at indicated time points to evaluate AUC(0-12) PK parameter of gepotidacin.

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours and 8-12 hours post dose

  24. AUC(0-24) of Gepotidacin

    Urine samples were collected from participants at indicated time points to evaluate AUC(0-24) PK parameter of gepotidacin.

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours and 12-24 hours post dose

  25. AUC(0-48) of Gepotidacin

    Urine samples were collected from participants at indicated time points to evaluate AUC(0-48) PK parameter of gepotidacin.

    Time frame: Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post dose

07

Results

Posted Dec 17, 2019

Participant flow

This was a Phase I, non-randomized, open-label, parallel-group, multi-center, two-part study that evaluated the pharmacokinetics, safety, and tolerability of a single 1500 milligrams (mg) oral dose of gepotidacin in participants with normal hepatic function and in participants with mild, moderate, and severe hepatic impairment.

Part 1, Up to 3 Days
Participant flow — Part 1, Up to 3 Days
MilestoneParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Started880
Completed780
Not completed100
Withdrew: Adverse event100
Part 2, Up to 3 Days
Participant flow — Part 2, Up to 3 Days
MilestoneParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Started808
Completed808
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate pharmacokinetic (PK) parameters. PK parameter population consist of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. This population was used in the assessment and characterization of PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin
Hours*nanograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin15894.7 ± 44.119505.7 ± 42.625415.5 ± 30.1
PrimaryMaximum Observed Concentration (Cmax) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Observed Concentration (Cmax) for Plasma Gepotidacin
Nanograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Maximum Observed Concentration (Cmax) for Plasma Gepotidacin3196.8 ± 85.03913.7 ± 64.15541.8 ± 42.7
SecondaryAUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin
Hours*nanograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC [0-t]) for Plasma Gepotidacin15512.9 ± 45.819151.6 ± 43.425066.8 ± 30.5
SecondaryTime to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Median · Hours
Time to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin
HoursParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Time to First Occurrence (Tmax) of Cmax for Plasma Gepotidacin3.000 (1.50 to 6.00)2.750 (2.50 to 4.00)2.250 (0.50 to 4.00)
SecondaryLag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Median · Hours
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin
HoursParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) for Plasma Gepotidacin0.50 (0.0 to 2.5)0.00 (0.0 to 1.0)0.00 (0.0 to 1.0)
SecondaryApparent Oral Clearance (CL/F) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Liters per hours
Apparent Oral Clearance (CL/F) for Plasma Gepotidacin
Liters per hoursParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Apparent Oral Clearance (CL/F) for Plasma Gepotidacin94.37 ± 44.176.90 ± 42.659.02 ± 30.1
SecondaryApparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin
LitersParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Apparent Volume of Distribution of the Terminal Phase (Vz/F) for Plasma Gepotidacin1235.3 ± 57.5944.7 ± 50.3699.1 ± 41.7
SecondaryTerminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Per hour
Terminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin
Per hourParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Terminal-phase Rate Constant (Lambda_z) for Plasma Gepotidacin0.07639 ± 14.90.08140 ± 12.30.08443 ± 15.2
SecondaryTerminal Phase Half Life (t1/2) for Plasma Gepotidacin

Blood samples were collected from participants at indicated time points after the administration of study treatment to investigate PK parameters.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · Hours
Terminal Phase Half Life (t1/2) for Plasma Gepotidacin
HoursParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Terminal Phase Half Life (t1/2) for Plasma Gepotidacin9.073 ± 14.98.515 ± 12.38.210 ± 15.2
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Single 12-lead ECG was obtained in a semi-supine position after 5 minutes rest using an ECG machine. Safety Population consists of all participants who received at least 1 dose of study drug and had at least one postdose safety assessment. Number of participants with abnormal-clinically significant and abnormal-not clinically significant values has been presented. Absolute QTc Interval \>450 milliseconds (msec), absolute PR interval \<110 msec and absolute QRS interval \<75 msec was considered as clinically significant ECG findings.

Time frame:
1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
1.5 hours, not clinically significant163
1.5 hours, clinically significant000
2 hours, not clinically significant565
2 hours, clinically significant000
4 hours, not clinically significant665
4 hours, clinically significant000
8 hours, not clinically significant354
8 hours, clinically significant000
12 hours, not clinically significant242
12 hours, clinically significant000
24 hours, not clinically significant655
24 hours, clinically significant000
36 hours, not clinically significant254
36 hours, clinically significant000
48 hours, not clinically significant455
48 hours, clinically significant000
SecondaryChange From Baseline Values in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs were measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Mean · Millimeters of mercury
Change From Baseline Values in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
SBP, 1.5 hours-10.4 ± 15.19-6.1 ± 11.86-3.8 ± 7.65
SBP, 2 hours-10.3 ± 10.99-7.5 ± 7.82-0.1 ± 11.96
SBP, 4 hours-6.2 ± 11.53-3.0 ± 8.850.5 ± 9.61
SBP, 8 hours-10.1 ± 9.64-0.5 ± 8.25-2.9 ± 6.79
SBP, 12 hours-5.1 ± 9.43-0.6 ± 8.00-1.9 ± 12.78
SBP, 24 hours-9.8 ± 15.75-6.6 ± 11.58-4.9 ± 8.10
SBP, 36 hours-7.3 ± 13.982.0 ± 8.86-2.6 ± 12.64
SBP, 48 hours-6.7 ± 13.08-10.6 ± 19.38-5.3 ± 14.04
DBP, 1.5 hours-6.8 ± 8.84-3.5 ± 7.051.1 ± 9.25
DBP, 2 hours-6.4 ± 6.13-5.1 ± 6.292.4 ± 7.17
DBP, 4 hours-3.8 ± 7.12-0.9 ± 6.753.4 ± 6.19
DBP, 8 hours-7.0 ± 4.80-2.9 ± 5.51-0.8 ± 7.69
DBP, 12 hours-5.4 ± 3.64-3.1 ± 6.241.9 ± 7.26
DBP, 24 hours-8.4 ± 8.69-3.4 ± 12.00-1.0 ± 10.68
DBP, 36 hours-9.3 ± 7.26-1.3 ± 5.50-1.1 ± 6.33
DBP, 48 hours-6.6 ± 8.380.9 ± 11.320.8 ± 6.18
SecondaryChange From Baseline Values in Heart Rate

Vital signs was measured in a semi-supine position after 5 minutes rest. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at 1.5 hours, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose
Reported as:
Mean · Beats per minute
Change From Baseline Values in Heart Rate
Beats per minuteParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
1.5 hours0.3 ± 7.470.6 ± 9.86-0.6 ± 6.50
2 hours-0.8 ± 7.98-0.1 ± 10.200.8 ± 5.60
4 hours-3.7 ± 8.791.4 ± 4.440.1 ± 6.77
8 hours-1.3 ± 7.912.6 ± 4.901.0 ± 4.93
12 hours3.9 ± 12.234.8 ± 3.585.1 ± 7.26
24 hours-4.3 ± 6.78-1.1 ± 6.64-2.0 ± 8.12
36 hours3.8 ± 9.763.8 ± 3.202.4 ± 9.68
48 hours-0.7 ± 3.942.8 ± 7.19-0.9 ± 6.56
SecondaryNumber of Participants With Serious Adverse Events (SAEs) and Non-SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
ParticipantsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Any Non-SAE324
Any SAE100
SecondaryNumber of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters

Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4, for urea, Creatine kinase (CK), creatinine, glucose, sodium, potassium, calcium, Aspartate Aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) levels, total and direct bilirubin, total protein, and albumin.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters
ParticipantsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Number of Participants With Toxicity Grading 3 or Higher for Clinical Chemistry Parameters016
SecondaryChange From Baseline Values for Clinical Chemistry Parameters: ALT, ALP, AST and CK

Blood samples were collected to analyze clinical chemistry parameters including: ALT, ALP, AST and CK. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Day 2
Reported as:
Mean · International units per liter
Change From Baseline Values for Clinical Chemistry Parameters: ALT, ALP, AST and CK
International units per literParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
ALT, Day 2-2.1 ± 5.90-0.1 ± 4.19-3.7 ± 6.59
ALP, Day 2-1.3 ± 7.98-4.4 ± 5.21-5.2 ± 4.36
AST, Day 2-1.8 ± 2.59-1.5 ± 4.31-7.8 ± 10.59
CK, Day 2-52.9 ± 57.31-36.4 ± 35.73-32.3 ± 79.05
SecondaryChange From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected to analyze clinical chemistry parameters including albumin and protein. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Day 2
Reported as:
Mean · Grams per liter
Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein
Grams per literParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Albumin, Day 2-1.3 ± 2.35-0.4 ± 1.60-1.7 ± 2.80
Protein, Day 2-0.9 ± 4.260.8 ± 2.82-3.5 ± 5.72
SecondaryChange From Baseline Values for Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected to analyze clinical chemistry parameters including bilirubin, direct bilirubin and creatinine. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Day 2
Reported as:
Mean · Micromoles per liter
Change From Baseline Values for Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Bilirubin, Day 2-2.470 ± 4.6131-1.924 ± 4.9592-7.695 ± 12.6932
Creatinine, Day 2-3.2413 ± 5.979277.6245 ± 15.89752-0.4420 ± 4.83379
Direct bilirubin, Day 2-0.3230 ± 0.71250-0.5771 ± 0.89060-1.8525 ± 2.71759
SecondaryChange From Baseline Values for Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Urea

Blood samples were collected to analyze clinical chemistry parameters including calcium, glucose, potassium, sodium and urea. Baseline is defined as Day 1 (Pre-Dose). Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Day 2
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Urea
Millimoles per literParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Calcium, Day 2-0.00831 ± 0.065033-0.01623 ± 0.059119-0.05488 ± 0.092641
Glucose, Day 2-0.08016 ± 0.5141030.04855 ± 0.755546-0.79563 ± 2.183639
Potassium, Day 20.01 ± 0.4810.35 ± 0.3070.02 ± 0.337
Sodium, Day 2-0.4 ± 1.670.6 ± 2.330.7 ± 1.97
Urea, Day 20.1983 ± 0.929420.4909 ± 1.293360.2975 ± 0.57194
SecondaryNumber of Participants With Toxicity Grading 3 or Higher for Hematology Parameters

Blood samples were collected to measure the number of participants with toxicity grades higher than 3 or 4 for blood neurtophils and blood platelets.

Time frame:
Up to 15 days
Reported as:
Count of participants · Participants
Number of Participants With Toxicity Grading 3 or Higher for Hematology Parameters
ParticipantsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Number of Participants With Toxicity Grading 3 or Higher for Hematology Parameters002
SecondaryNumber of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters

Urine samples were collected and specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones were analyzed by dipstick method.

Time frame:
Up to 15 days
Reported as:
Count of participants · Participants
Number of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters
ParticipantsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Number of Participants With Toxicity Grading 3 or Higher for Urinalysis Parameters000
SecondaryNumber of Participants With Abnormal Findings During Physical Examinations

A complete physical examination included, at a minimum, assessments of the skin, cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.

Time frame:
Pre-dose up to 31 days prior to dosing

No measurements were reported for this outcome.

SecondaryTotal Unchanged Drug (Ae_total) and Amount of Drug Excreted in Urine in a Time Intervals (Ae (t1-t2) for Gepotidacin

Urine samples were collected from participants at indicated time points. Ae_total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Ae (t1-t2) was the amount of drug excreted in urine in time intervals for predose, 0 to 6, 6 to 12, 12 to 24, 24 to 36, and 36 to 48 hours after dosing for participants with hepatic impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participants with normal hepatic function. It was calculated by multiplication of the urine concentration for a time interval and the length of this time interval.

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Reported as:
Mean · Milligrams
Total Unchanged Drug (Ae_total) and Amount of Drug Excreted in Urine in a Time Intervals (Ae (t1-t2) for Gepotidacin
MilligramsParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Ae_total, n=6, 6, 6127.67 ± 63.552191.39 ± 84.368325.31 ± 124.273
Ae (0-2), n=8, 0, 05.82 ± 7.838——
Ae (2-4), n=9, 0, 055.53 ± 55.735——
Ae (4-6), n=9, 0, 028.79 ± 19.702——
Ae (0-6), n=0, 7, 8—144.24 ± 104.112199.28 ± 103.407
Ae (6-8), n=9, 0, 018.67 ± 8.371——
Ae (6-12), n=0, 7, 8—60.53 ± 35.231112.65 ± 93.439
Ae (8-12), n=9, 0, 016.21 ± 7.056——
Ae (12-24), n=7, 6, 711.15 ± 6.00712.72 ± 7.26523.27 ± 17.258
Ae (24-36), n=8, 7, 76.62 ± 4.6758.44 ± 3.91412.78 ± 6.869
Ae (36-48), n=6, 8, 73.71 ± 1.8454.59 ± 3.5126.04 ± 2.909
SecondaryPercentage of the Given Dose of Drug Excreted in Urine (Fe%)

Urine samples were collected from participants at indicated time points. Percentage of the given dose of drug excreted in urine was calculated as: (Ae_total divided by Dose) and multiplied by 100.

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Reported as:
Mean · Percentage of drug
Percentage of the Given Dose of Drug Excreted in Urine (Fe%)
Percentage of drugParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Percentage of the Given Dose of Drug Excreted in Urine (Fe%)8.51 ± 4.23712.76 ± 5.62521.69 ± 8.285
SecondaryRenal Clearance (CLr) of Gepotidacin

Urine samples were collected from participants at indicated time points. Renal clearance for gepotidacin was calculated as Ae_total divided by AUC (0-t).

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose
Reported as:
Mean · Liters per hour
Renal Clearance (CLr) of Gepotidacin
Liters per hourParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
Renal Clearance (CLr) of Gepotidacin8.18 ± 3.2099.45 ± 2.71012.46 ± 3.911
SecondaryAUC(0-12) of Gepotidacin

Urine samples were collected from participants at indicated time points to evaluate AUC(0-12) PK parameter of gepotidacin.

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours and 8-12 hours post dose
Reported as:
Mean · Hours*micrograms per milliliter
AUC(0-12) of Gepotidacin
Hours*micrograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
AUC(0-12) of Gepotidacin1201 ± 1033.53030 ± 2245.54771 ± 4678.3
SecondaryAUC(0-24) of Gepotidacin

Urine samples were collected from participants at indicated time points to evaluate AUC(0-24) PK parameter of gepotidacin.

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours and 12-24 hours post dose
Reported as:
Mean · Hours*micrograms per milliliter
AUC(0-24) of Gepotidacin
Hours*micrograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
AUC(0-24) of Gepotidacin1269 ± 1040.42925 ± 1868.35807 ± 5151.0
SecondaryAUC(0-48) of Gepotidacin

Urine samples were collected from participants at indicated time points to evaluate AUC(0-48) PK parameter of gepotidacin.

Time frame:
Pre-dose, 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post dose
Reported as:
Mean · Hours*micrograms per milliliter
AUC(0-48) of Gepotidacin
Hours*micrograms per milliliterParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
AUC(0-48) of Gepotidacin1394 ± 1252.43547 ± 1667.95035 ± 4695.6

Adverse events

Collected over Non-serious AEs and SAEs were collected from the start of the treatment up to 15 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Normal Hepatic Function1/9 (11.1%)1/9 (11.1%)3/9 (33.3%)
Participants With Moderate Hepatic Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Participants With Severe Hepatic Impairment0/8 (0%)0/8 (0%)4/8 (50%)
Most frequent serious events
Most frequent serious events
EventParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
DeathGeneral disorders1/90/80/8
Most frequent other events
Most frequent other events
EventParticipants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
DiarrhoeaGastrointestinal disorders3/92/82/8
NauseaGastrointestinal disorders0/90/81/8
HeadacheNervous system disorders0/91/81/8
LeukopeniaBlood and lymphatic system disorders0/90/81/8
Wrist fractureInjury, poisoning and procedural complications0/91/80/8
Decreased appetiteMetabolism and nutrition disorders0/90/81/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic ImpairmentTotal
Mean59.8 ± 5.7062.5 ± 7.1958.1 ± 6.1560.1 ± 6.34
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic ImpairmentTotal
Female1102
Male87823
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants With Normal Hepatic FunctionParticipants With Moderate Hepatic ImpairmentParticipants With Severe Hepatic ImpairmentTotal
Asian - Central/South Asian Heritage0011
African American/African Heritage3003
White - White/Caucasian/European Heritage68721
08

Study locations

2 sites
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Dec 2018, 6 months.

Results were first posted in Dec 2019, 11 months after primary completion.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 6 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
Jun 19, 2018
StartActual
Jun 14, 2018
Primary completionActual
Dec 26, 2018
CompletionActual
Dec 26, 2018
Results first posted
Dec 17, 2019
Last update
Apr 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03562117
Lead sponsor
GlaxoSmithKline
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Jun 19, 2018
Start date
Jun 14, 2018
Primary completion
Dec 26, 2018
Completion
Dec 26, 2018
Results posted
Dec 17, 2019
Last update
Apr 12, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion